Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Overview of attention for article published in Arthritis Research & Therapy, May 2017

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 35 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 201 followers.

Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling. https://t.co/mxsjfVfCnF

09 Mar 2018

Reply Repost Favourite

PC | #ArthritisResTher Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation… https://t.co/cj8UoiiAQO

17 May 2017

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.